All In Biotech

Drug Trial Radar · NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Aug 20, 2025

Primary completion

Jul 8, 2028

Study completion Jul 8, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules. In the second part of the study, groups of people will receive the study drug in dosing regimens deemed to be safe in Part 1. In the third part of the study, people will receive the study drug together with other anti-cancer medicines.

Conditions

  • Advanced/Metastatic Solid Tumors
  • Bladder Cancer
  • Urothelial Carcinoma
  • Advanced Non-Small Cell Lung Cancer
  • Carcinoma, Non Small Cell Lung
  • Carcinoma, Squamous Cell of Head and Neck
  • Head and Neck Cancer
  • Esophageal Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Squamous Cell Carcinoma
  • Esophageal Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Pancreatic Cancer

Interventions

  • PF-08046876Drug

    Intravenous administration

  • PembrolizumabCombination product

    Intravenous administration

  • CisplatinCombination product

    Intravenous administration

  • CarboplatinCombination product

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluationTime frame: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
  2. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): MonotherapyTime frame: Baseline to end of DLT evaluation period
  3. Part 1: Recommended Monotherapy Dose for ExpansionTime frame: Baseline to 30 days post last study drug administration
  4. Part 2: Recommended Monotherapy Phase 2 DoseTime frame: Baseline to 30 days post last study drug administration
  5. Part 3: Recommended Combination Phase 2 Dose/ Recommended Combination Dose for ExpansionTime frame: Baseline to 30 days post last study drug administration

Locations

31 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • Administrative Address: UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • Santa Monica UCLA Medical Center & Orthopaedic Hospital

    Santa Monica, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Smilow Cancer Hospital - Yale New Haven Health

    New Haven, Connecticut · Recruiting

  • Yale - New Haven Hospital - Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Phase 1 Unit

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital - Trumbull

    Trumbull, Connecticut · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute - Chestnut Hill

    Newton, Massachusetts · Recruiting

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center - Conroe

    Conroe, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - West Houston

    Houston, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - League City

    League City, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - Sugar Land

    Sugar Land, Texas · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Pan American Center for Oncology Trials, LLC

    Rio Piedras, Puerto Rico · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [barcelona], Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.